OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

London and New York, NY, February 12, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy,...
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

London and New York, NY, January 31, 2025 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy,...
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

London and New York, NY, January 22, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy,...